BIA-ALCL-Horizon Scanning
Patrick Mallucci1, Giovanni Bistoni2,3
1Director of Plastic Surgery at Mallucci London, 13 crescent Place, London, SW3 2EA, UK.
JPRAS Open
|December 9, 2022
Summary
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) remains controversial, with ongoing debate regarding its causes and frequency. Experts disagree on implant choices and patient guidance, despite advances in diagnosis and treatment.
Area of Science:
- Oncology
- Plastic Surgery
- Biomaterials Science
Background:
- Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) has become a significant concern in breast implant surgery.
- Despite advances, considerable debate persists regarding the etiology and incidence of BIA-ALCL.
- Disagreements exist among experts on fundamental aspects like implant selection and patient counseling.
Purpose of the Study:
- To present the authors' viewpoint on BIA-ALCL based on current literature and data.
- To highlight areas of ongoing controversy and expert division regarding BIA-ALCL.
- To synthesize current knowledge on BIA-ALCL diagnosis, prognosis, and treatment.
Main Methods:
- Literature review and analysis of available data on BIA-ALCL.
- Synthesis of expert opinions and professional debates surrounding BIA-ALCL.
- Critical evaluation of current understanding of BIA-ALCL etiology and incidence.
Main Results:
- BIA-ALCL diagnosis, prognosis, and treatment are increasingly understood.
- Significant debate continues regarding the underlying causes and actual frequency of BIA-ALCL.
- Divergent expert opinions exist on optimal breast implant selection and patient advisory strategies.
Conclusions:
- Further research is needed to resolve debates on BIA-ALCL etiology and incidence.
- Consensus building is required for standardized recommendations on breast implant use and patient care.
- The authors' perspective is based on current evidence, acknowledging ongoing scientific discourse.
